Kazem I, van den Broek P, Huygen P L
Int J Radiat Oncol Biol Phys. 1982 Sep;8(9):1533-7. doi: 10.1016/0360-3016(82)90613-7.
One hundred ten patients with predominantly advanced laryngeal carcinoma were treated in the period 1969-1978 with planned preoperative radiation therapy followed by surgery. Site distribution was: 63 supraglottic, 26 glottic, 15 transglottic and 6 subglottic. There were 4 Stage II patients, 66 Stage III and 40 Stage IV. Preoperative radiation therapy consisted of Telecobalt irradiation to a total dose of 25 Gy given to a target volume encompassing the larynx and regional neck nodes, given in 5 equal daily fractions of 5 Gy in 5 consecutive days. Surgery was performed 2 days later. Total laryngectomy was performed on 48 patients, total laryngectomy with neck dissection on 55 patients, supraglottic laryngectomy on 5 and supraglottic laryngectomy with neck dissection on 2 patients. Crude actuarial 5 and 10 year survival probability for the whole group is 71 and 61%, respectively. The corrected 5 and 10 year survival is 75%. For patients with T3-T4-N0 tumors 5 and 10 year survival probability is: crude 65 and 58%, and corrected 70% respectively. For T3-T4-N+ crude: 75 and 60% and corrected: 78%. Of 110 patients, one died postoperative, three died of intercurrent disease, five died as a result of second malignancy, and 23 died of their larynx carcinoma: 12/23 because of locoregional failure, and 11/23 because of distant metastasis. We concluded that short intensive preoperative radiation therapy and surgery offer a high cure rate in the treatment of advanced resectable laryngeal carcinoma. The merits of this technique are outlined in the text.
1969年至1978年期间,对110例以晚期喉癌为主的患者进行了计划性术前放疗,随后进行手术。病变部位分布如下:声门上型63例,声门型26例,跨声门型15例,声门下型6例。其中Ⅱ期患者4例,Ⅲ期66例,Ⅳ期40例。术前放疗采用远距离钴治疗,总剂量为25 Gy,照射靶区包括喉部及颈部区域淋巴结,连续5天,每天分5次给予,每次5 Gy。2天后进行手术。48例行全喉切除术,55例行全喉切除术加颈部淋巴结清扫术,5例行声门上喉切除术,2例行声门上喉切除术加颈部淋巴结清扫术。全组患者的粗略精算5年和10年生存率分别为71%和61%。校正后的5年和10年生存率为75%。T3 - T4 - N0肿瘤患者的5年和10年生存率为:粗略生存率分别为65%和58%,校正后为70%。T3 - T4 - N +患者粗略生存率为75%和60%,校正后为78%。110例患者中,1例术后死亡,3例死于并发疾病,5例死于第二原发恶性肿瘤,23例死于喉癌:23例中有12例死于局部区域复发,11例死于远处转移。我们得出结论,短期强化术前放疗和手术治疗晚期可切除喉癌的治愈率较高。本文概述了该技术的优点。